Rockefeller Capital Management L.P. Has $136.79 Million Stock Holdings in Abbott Laboratories $ABT

Rockefeller Capital Management L.P. increased its position in Abbott Laboratories (NYSE:ABT) by 16.4% in the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 1,005,706 shares of the healthcare product maker’s stock after acquiring an additional 141,597 shares during the quarter. Rockefeller Capital Management L.P.’s holdings in Abbott Laboratories were worth $136,786,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Cornerstone Advisors LLC lifted its holdings in shares of Abbott Laboratories by 7.2% during the second quarter. Cornerstone Advisors LLC now owns 88,800 shares of the healthcare product maker’s stock worth $12,078,000 after purchasing an additional 6,000 shares during the period. Citizens Financial Group Inc. RI raised its position in Abbott Laboratories by 39.9% during the 2nd quarter. Citizens Financial Group Inc. RI now owns 131,350 shares of the healthcare product maker’s stock worth $17,865,000 after purchasing an additional 37,463 shares during the last quarter. Hedeker Wealth LLC acquired a new position in Abbott Laboratories during the 2nd quarter worth about $763,000. Jensen Investment Management Inc. grew its position in shares of Abbott Laboratories by 74.2% in the 2nd quarter. Jensen Investment Management Inc. now owns 2,378,563 shares of the healthcare product maker’s stock valued at $323,508,000 after buying an additional 1,012,778 shares during the last quarter. Finally, Avantax Advisory Services Inc. raised its position in shares of Abbott Laboratories by 1.0% during the second quarter. Avantax Advisory Services Inc. now owns 182,452 shares of the healthcare product maker’s stock worth $24,815,000 after acquiring an additional 1,867 shares during the last quarter. 75.18% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several analysts recently commented on the company. Mizuho upped their target price on Abbott Laboratories from $135.00 to $140.00 and gave the company a “neutral” rating in a report on Tuesday, October 14th. Benchmark assumed coverage on shares of Abbott Laboratories in a research report on Friday, October 10th. They set a “buy” rating and a $145.00 price objective for the company. Sanford C. Bernstein upped their price target on shares of Abbott Laboratories from $145.00 to $150.00 and gave the company an “outperform” rating in a research report on Thursday, October 16th. Jefferies Financial Group boosted their price objective on Abbott Laboratories from $145.00 to $149.00 and gave the company a “buy” rating in a research note on Thursday, October 16th. Finally, The Goldman Sachs Group lifted their target price on Abbott Laboratories from $153.00 to $157.00 and gave the stock a “buy” rating in a report on Wednesday, October 1st. Two analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $147.00.

Abbott Laboratories Trading Up 1.0%

NYSE ABT opened at $130.59 on Friday. Abbott Laboratories has a one year low of $110.86 and a one year high of $141.23. The company has a debt-to-equity ratio of 0.25, a current ratio of 1.82 and a quick ratio of 1.30. The business’s fifty day moving average is $130.38 and its 200-day moving average is $131.35. The stock has a market capitalization of $227.08 billion, a price-to-earnings ratio of 16.36, a PEG ratio of 2.36 and a beta of 0.68.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings data on Wednesday, October 15th. The healthcare product maker reported $1.30 earnings per share for the quarter, hitting the consensus estimate of $1.30. The company had revenue of $11.37 billion during the quarter, compared to analyst estimates of $11.40 billion. Abbott Laboratories had a return on equity of 17.78% and a net margin of 31.88%.The firm’s revenue for the quarter was up 6.9% on a year-over-year basis. During the same quarter last year, the firm posted $1.21 EPS. Abbott Laboratories has set its FY 2025 guidance at 5.120-5.180 EPS. Equities research analysts predict that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, November 17th. Stockholders of record on Wednesday, October 15th will be issued a $0.59 dividend. This represents a $2.36 dividend on an annualized basis and a dividend yield of 1.8%. The ex-dividend date of this dividend is Wednesday, October 15th. Abbott Laboratories’s dividend payout ratio (DPR) is presently 29.57%.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.